相关实验视频

Updated: Jan 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

延迟治疗与高度未差异化形肉瘤的生存率较差有关

Aidan C O'Brien¹, Sawyer H Farmer¹, Prajeeth K Koyada²

¹Albany Medical College, Albany, New York.

The Journal of surgical research

|December 13, 2025

概括

延迟开始治疗显著降低了高度未分化形肉瘤的患者的生存率. 及时治疗对于这些软组织肉瘤患者的更好的结果至关重要.

科学领域:

在瘤学瘤学.
手术病理学手术病理学
临床研究临床研究

背景情况:

治疗开始的时间对各种癌症的存活率产生影响.
治疗延迟在软组织肉瘤,特别是高等级不分化的多形肉瘤 (UPS) 中的作用尚不清楚.
对组织学亚型的个性化评估是以患者为中心的护理的关键.

研究的目的:

调查治疗开始时间和生存率之间的关联.
专门分析在被诊断为局部,高等级UPS的患者中这种关联.

主要方法:

来自国家癌症数据库 (2004-2021) 的6220名局部高等级UPS患者的回顾性分析.
排除不符合条件的病例,以确保研究队列的完整性.
应用Kaplan-Meier和多变量Cox比例危险模型来评估相对于治疗延迟的生存结果.

主要成果:

诊断后超过4周开始治疗与5年生存率显著下降有关 (P < 0.001).
对于四肢和干部瘤,较长的治疗开始延迟与较差的生存率独立相关 (HR = 1.01 每周;P = 0.013).
在头部和部或腹部/盆腔瘤中,治疗延迟和生存率之间没有显著的关联.

结论:

治疗开始的时间延长是局部,高档UPS在四肢和干部生存率降低的独立预测因素.
观察到治疗开始时间的增加可能源于不断变化的诊断程序和与保险有关的延迟.
这些发现强调了针对特定软组织肉瘤亚型的及时治疗的重要性.

关键词:

国家癌症数据库.软组织肉瘤是软组织肉瘤.幸存的生存方式时间到治疗启动时间.不分化的多形形肉瘤.

更多相关视频

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...